Literature DB >> 31568111

Buprenorphine Use in Palliative Care.

Katie Fitzgerald Jones1.   

Abstract

Palliative care is encountering an increasing number of patients with opioid use disorder who are managed on medication-assisted treatment. Buprenorphine is US Food and Drug Administration approved for office-based management of opioid use disorder. As a partial opioid agonist, it can be used to manage pain in the palliative care setting but can also pose inherent challenges to the management of pain that necessitates full opioid agonists. This article uses a case example to highlight the management of substance use disorder and pain in a patient on buprenorphine along the full illness trajectory. In addition, an overview of buprenorphine pharmacology, unique aspects of the prescribing waiver, and pain management will be discussed.

Entities:  

Year:  2019        PMID: 31568111     DOI: 10.1097/NJH.0000000000000598

Source DB:  PubMed          Journal:  J Hosp Palliat Nurs        ISSN: 1522-2179            Impact factor:   1.918


  2 in total

1.  Consensus-Based Guidance on Opioid Management in Individuals With Advanced Cancer-Related Pain and Opioid Misuse or Use Disorder.

Authors:  Katie Fitzgerald Jones; Dmitry Khodyakov; Robert Arnold; Hailey Bulls; Emily Dao; Jennifer Kapo; Diane Meier; Judith Paice; Jane Liebschutz; Christine Ritchie; Jessica Merlin
Journal:  JAMA Oncol       Date:  2022-08-01       Impact factor: 33.006

2.  A Case Study of Pain Management at End-of-Life for a Patient on High-Dose Buprenorphine.

Authors:  Naomi T Katz; Martyn Lloyd-Jones; Lucy Demediuk; Kerry McLaughlin; Megan McKechnie; Michelle Gold
Journal:  J Patient Exp       Date:  2022-02-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.